Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCRX.L Regulatory News (CRX)

  • There is currently no data for CRX

Directorate Change

25 Feb 2009 07:00

RNS Number : 8182N
Cyprotex PLC
25 February 2009
 



25 February 2009

Cyprotex PLC ('Cyprotex' or the 'Company')

Directorate changes

Cyprotex PLC (AIM: CRX) today announces the resignation of David Evans as a Non-executive Director of the Company with immediate effect and the appointment of John Dootson as Chief Financial Officer effective from 2 March 2009.

Commenting on the directorate changes, Steve Harris, Chairman of Cyprotex said: 

"David has made a significant contribution to the Company as a Non-executive Director and the Board would like to thank him for his contribution to the Company and wish him well with his future endeavours. 

The Company is very pleased to appoint John Dootson as Chief Financial Officer. John has been associated with the Company for over four years as a consultant Financial Controller and therefore has intimate knowledge of the Company's business and finances. He brings to the Company wide ranging financial expertise gained in both industry and private practice"

Notes for Editors: 

John Dootson, aged 47, has 25 years experience in both professional practice and in industry. Trained with Tenon and Ernst & Young, John has extensive managerial experience in major accounting practices and has worked on a wide range of projects including London Stock Exchange flotations and circulars, corporate governance, company acquisitions and disposals and specialist advice to growing SMEs. John has also worked in a number of roles in Industry at Financial Controller and Director level, including seven years within the senior head office finance team of BTP plc, a former FTSE250 specialty chemical manufacturer with over 50 sites worldwide prior to its sale to Clariant AG for £1.1bn.

John is a Fellow of the Institute of Chartered Accountants in England and Wales and for the last four years he has assisted Cyprotex in a management consultative role that has included all aspects of finance and reporting.

The following information relating to Mr. Dootson is provided in compliance with the provisions of Rule 17, Schedule Two, paragraph (g) of the AIM Rules for Companies

 

Full name and age: John Kevin Dootson, age 47.

Present directorships: Downham Mayer Clarke Limited

 

Directorships during the past five years:  Downham Mayer Clarke Limited

Mr. Dootson has not been a director of any company which has been wound up or placed in administration or receivership.

Mr. Dootson holds no shares in the Company. 

There are no further disclosures to be made in respect of Mr. Dootson under the provisions of Rule 17, Schedule Two, paragraph (g) of the AIM Rules for Companies.

 

Enquiries:

Cyprotex PLC

 

Tony BaxterCEO 

01625 505100

Mark WarburtonCompany Secretary

 

Noble & Company Limited

 

John Llewellyn-Lloyd 

 02077632200

Sam Reynolds

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOATIMATMMITBJL
Date   Source Headline
10th Oct 20169:03 amRNSForm 8.5 (EPT/RI) - Cyprotex PLC
7th Oct 20169:36 amRNSForm 8.5 (EPT/RI) - Cyprotex PLC
6th Oct 20165:15 pmRNSConversion of Loan Notes & TVR
6th Oct 20167:00 amRNSNew DDI-Fusion
5th Oct 20169:11 amRNSForm 8.5 (EPT/RI) - Cyprotex PLC
3rd Oct 20169:50 amRNSForm 8.5 (EPT/RI) - Cyprotex PLC
30th Sep 20169:26 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
29th Sep 20169:42 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
27th Sep 20169:34 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
26th Sep 201610:02 amRNSForm 8.3 - Cyprotex Plc
26th Sep 20169:25 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
26th Sep 20167:00 amRNSAppointment of new Director of US Operations
23rd Sep 20169:10 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
21st Sep 20169:29 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
20th Sep 20169:09 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
19th Sep 20169:42 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
16th Sep 20163:52 pmRNSForm 8.3 - Cyprotex plc
16th Sep 20169:36 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
15th Sep 201610:33 amRNSForm 8.3 - Cyprotex plc
15th Sep 201610:05 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
13th Sep 20169:33 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
13th Sep 20167:00 amRNSExtension of metabolite identification service
12th Sep 201612:31 pmRNSForm 8.3 - Cyprotex plc
9th Sep 20169:15 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
8th Sep 20167:00 amRNSExpansion ADME capabilities (8 transporter assays)
7th Sep 20169:43 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
6th Sep 201610:08 amRNSForm 8.5 (EPT/RI) - Cyprotex PLC
2nd Sep 20169:12 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
1st Sep 20169:31 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
31st Aug 20169:47 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
30th Aug 20169:28 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
26th Aug 20169:34 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
25th Aug 20169:39 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
25th Aug 20167:00 amRNSInstallation of two mass spectrometer systems
23rd Aug 20169:39 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
22nd Aug 201610:01 amRNSForm 8.5 (EPT/RI)
17th Aug 201611:24 amRNSForm 8.3 - Cyptotex Plc
17th Aug 20169:39 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
16th Aug 20169:25 amRNSForm 8.5 (EPT/RI) - Cyprotex PLC
15th Aug 201610:52 amRNSForm 8.3 - Cyprotex Plc
15th Aug 20169:13 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
12th Aug 20169:29 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
11th Aug 20169:15 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
10th Aug 201611:14 amRNSForm 8.3 - Cyprotex Plc
10th Aug 20169:14 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
9th Aug 20169:14 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
8th Aug 201611:10 amRNSForm 8.3 - Cyprotex
8th Aug 20169:29 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
5th Aug 201611:00 amRNSForm 8.3 - Cyprotex Plc
5th Aug 20169:32 amRNSForm 8.3 - Cyprotex PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.